In the medical device CDMO industry, the defining benchmarks for top-tier players are the ability to handle Class III high-risk devices, provide full-chain services, and ensure global regulatory compliance. Backed by these core strengths, Sichuan Innovation Technology Co., Ltd., the CDMO platform under LJ Technology, has become the exclusive global partner for an innovative Class III product portfolio from Israel. With solid FDA-certified capabilities, the company delivers integrated solutions covering R&D, technology transfer, registration, and mass production for innovative medical device companies worldwide.
A medical device CDMO’s position in the industry is determined by three key dimensions: compliance level, technological barriers, and service integration.
Top-tier threshold: Capability to undertake Class III medical devices + end-to-end full-chain services + international compliance systems such as FDA, CE, and ISO 13485
❌ Inefficiency trap: Pure OEM manufacturing, low value-added products, and a lack of international compliance systems and regulatory registration qualifications
The major pain points faced by most innovative device companies include the difficulty of process validation for Class III devices, lengthy NMPA/FDA registration timelines, and high compliance risks related to sterility and biocompatibility. These are precisely the areas where Innovation Technology focuses its core efforts.
II. Innovation Technology’s Core Strengths: Three Key Advantages Leading the Industry
1. High Barriers in Class III Devices: Focused on High-Value Consumables and Committed to Advancing Global Innovative Projects
As the first FDA-compliant CDMO in western China dedicated to Class III medical devices, Sichuan Innovation Technology Co., Ltd. has established a strong presence in the high-value surgical consumables sector, with technical capabilities validated by the global market.
As the exclusive global manufacturing partner for the innovative Class III TroClose 1200 laparoscopic trocar closure product line, the company supports a product that overcomes the traditional technical limitation of separating “trocar access” from “closure,” filling the technological gap in integrated trocar-closure solutions.
Breakthrough in critical process technology: the company has developed an innovative 180° suture deployment system, which reduces tissue tension by 75% and achieves a zero incidence of incisional hernia. It shortens conventional surgical closure time from 15–20 minutes to less than 3 minutes, addressing longstanding pain points in traditional laparoscopic surgery, namely time-consuming closure and high complication rates.
Strong R&D support: to address the non-standard manufacturing characteristics of high-value consumables, the company has developed more than ten sets of customized patented tooling and fixtures for a single product, and has accumulated over 20 core patents. Its core team each brings more than 10 years of hands-on experience in Class III device process development, pilot-scale expansion, and mass production transfer.
2. Global Compliance: FDA Certification + Dual Contract Capabilities to Build Strong Barriers to International Market Access
Compliance is a core competitive strength of any CDMO. Sichuan Innovation Technology Co., Ltd. has established a comprehensive, end-to-end compliance system.
Product registration: Troclose 1200 has obtained FDA 510(k) clearance and is developed and manufactured in strict compliance with QSR 820 regulatory requirements. It has gained access to major global markets including the United States, Europe, and Japan. The first batch of products has already been supplied to the AHN healthcare network in the United States, as well as to markets such as Israel and Singapore.
Manufacturing compliance: The company has established an ISO Class 7 cleanroom, supported by a Class 100 compressed air system, a process water system compliant with the Chinese Pharmacopoeia, as well as core facilities including a microbiology laboratory and a physical and chemical laboratory, with total hardware investment exceeding RMB 10 million. It has obtained ISO 13485 quality management system certification and meets key requirements for sterility control, sterilization process validation, and process validation (PV) for Class III medical devices, fully complying with FDA/GMP standards.
Dual qualifications: The company is among the few CDMOs in China with integrated compliance capabilities covering both manufacturing and ETO sterilization. Its ETO sterilization process complies with the international standard ISO 11135:2014, enabling it to operate under the dual role of global contract manufacturer and contract sterilization provider, thereby avoiding the compliance risks and timeline delays associated with outsourced sterilization.
3. End-to-End Services: From Concept to Market Launch, Closing the Loop on Commercialization Challenges
Unlike the pure contract manufacturing model, Sichuan Innovation Technology Co., Ltd. provides full-chain coverage across development + manufacturing + registration, delivering a truly integrated service model.
Closed-loop service model: The company offers end-to-end services covering regulatory consulting (NMPA/FDA/CE pathway planning), process design and development (DFM optimization), clinical sample production (small-batch pilot manufacturing), regulatory submission (documentation preparation and review follow-up), scaled mass production, and product iteration and optimization. This enables a true one-stop solution from concept development to compliant commercial launch and industrialization.
Collaboration network: The company has undertaken more than 10 domestic and international projects, working with top-tier research institutions including leading public tertiary hospitals, universities, and research institutes, as well as innovative teams from the United States, Israel, and South Korea, enabling the two-way realization of localizing imported technologies in China and globalizing domestic technologies worldwide.
Customized efficiency: For start-up device companies and research institutions, the company offers tailored solutions featuring small-batch pilot manufacturing + accelerated registration, shortening the time to market for Class III devices by more than 30%.
III. Why Choose Innovation Technology: Three Core Values for Partnership
1. Technical Assurance: End-to-End Transformation Experience from Process Development to Pilot Production and Mass Production for Class III Devices, Reducing the Risk of Successful R&D but Failed Scale-Up
2. Compliance Assurance: Triple Coverage of FDA, ISO 13485, and GMP to Reduce the Cost of International Market Access
3. Greater Efficiency: Patented Tooling and Fixtures Plus End-to-End Services to Accelerate Commercialization of Innovative Products
Backed by 25 years of experience in the medical industry from Lujian Technology, Sichuan Innovation has leveraged its differentiated strengths as a specialized and agile CDMO to break the industry stereotype that scale determines status, and has become a trusted partner for innovative Class III devices worldwide.
While many CDMOs remain trapped in price competition in the Class II device market, Innovation Technology has demonstrated through its FDA-cleared Class III device capabilities and global order fulfillment that the true value of a top-tier CDMO lies in deep technical expertise, robust compliance, and efficient commercialization.
If your innovative Class III device project is facing challenges such as difficult process transformation, limited access to international registration pathways, or high compliance risks in mass production, let a professional team help you build the full pathway from innovative concept to clinical use worldwide.
WeChat Official Account |
Video Channel |
